Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis

Kaija-Leena Kolho, Dan Turner, A. A. te Velde (Editor), L. Rodrigo (Editor), J. M. Pajares (Editor), A. Weimann (Editor), A. Amedei (Editor), A. W. Mangel (Editor)

Research output: Contribution to journalArticlepeer-review


Objective. To explore fecal calprotectin levels in pediatric ulcerative colitis (UC) in relation with the validated clinical activity index PUCAI. Methods. This study included all 37 children (median age 14 years) with UC who had calprotectin measured (PhiCal ELISA Test) by the time of PUCAI assessment at the Children's Hospital of Helsinki in a total of 62 visits. Calprotectin values <100 μg/g of stool were considered as normal. The best cut-off value of each measure to predict 3-month clinical outcome was derived by maximizing sensitivity and specificity. Results. In clinically active disease (PUCAI ≥ 10), calprotectin was elevated in 29/32 patients (91% sensitivity). When in clinical remission, 26% (8/30) of the children had normal calprotectin but 7 (23%) had an exceedingly high level (>1000 μg/g). The best cut-off value for calprotectin for predicting poor outcome was 800 μg/g (sensitivity 73%, specificity 72%; area under the ROC curve being 0.71 (95%CI 0.57–0.85)) and for the PUCAI best cut-off values >10 (sensitivity 62%, specificity 64%; area under the ROC curve 0.714 (95%CI 0.58–0.85)). Conclusion. The clinical relevance of somewhat elevated calprotectin during clinical remission in pediatric UC is not known and, until further evidence accumulates, does not indicate therapy escalation.
Original languageAmerican English
Article number179024
Pages (from-to)1-5
Number of pages5
JournalISRN Gastroenterology
StatePublished - 2013


Dive into the research topics of 'Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this